AllianceBernstein
BCAX

AllianceBernstein’s Bicara Therapeutics BCAX Stock Holding History

AllianceBernstein’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.11M Buy
55,990
+24,160
+76% +$539K ﹤0.01% 2338
2026
Q1 		$536K Buy
31,830
+2,720
+9% +$46.8K ﹤0.01% 2604
2025
Q4 		$490K Sell
29,110
-11,660
-29% -$199K ﹤0.01% 2668
2025
Q3 		$644K Sell
40,770
-4,790
-11% -$53.6K ﹤0.01% 2549
2025
Q2 		$423K Buy
+45,560
New +$543K ﹤0.01% 2731
2025
Q1 		– Sell
-821,264
Closed -$14.3M – 3238
2024
Q4 		$14.3M Buy
821,264
+113,261
+16% +$2.36M ﹤0.01% 1023
2024
Q3 		$18M Buy
+708,003
New +$18.1M 0.01% 945

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AllianceBernstein's BCAX Position: Q2 2026 in Review

AllianceBernstein increased its Bicara Therapeutics (BCAX) stake by 76% in Q2 2026, buying an estimated $539K and bringing the position to 55,990 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #2338.

AllianceBernstein first reported a position in BCAX in Q3 2024 and has held it in 7 quarters since. The position peaked at $18M in Q3 2024. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • AllianceBernstein held 55,990 shares of Bicara Therapeutics worth $1.11M as of Q2 2026.
  • AllianceBernstein bought 24,160 Bicara Therapeutics shares in Q2 2026, an estimated $539K.
  • Bicara Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #2338 holding.
  • AllianceBernstein first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • AllianceBernstein's Bicara Therapeutics position peaked at $18M in Q3 2024.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.